Executive Series: Reimbursement: The New Investment Hurdle
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element senior executives must evaluate. Payers’ increased power to restrict access and contract for reduced prices—combined with the growing use of evidence-based medicine to influence reimbursement policy—can profoundly impact potential revenues and, by extension, asset valuations. Many executives responsible for licensing decisions have ignored this increasingly important driver of valuation. At best, they begrudgingly recognize that they need to consider scenarios of price and access within their forecast models. Instead, they should embrace a nuanced knowledge of the payer environment as a means of differentiation.
Licensing executives are well aware of the fast-changing reimbursement climate, but too often their inability to gauge payers’ potential actions results in a “just say no” approach to certain deals. Instead, licensing parties should develop new deal structures, including reimbursement-based milestones, to limit potential risk associated with a diverse payer community. With a nuanced approach to payers and a strategic perspective on reimbursement, licensing teams—and those executives managing them—can find value others may have missed and avoid missteps driven by conventional thinking.
Participants in this interactive discussion will learn how a deep understanding and strategic perspective on reimbursement represents one of the few ways a licensing team can find value that others have missed. It may also prevent them from fundamentally misjudging the potential value of their assets.
Regional General Manager, Campbell Alliance
Practice Area Leader, Campbell Alliance
|What:||Reimbursement: The New Investment Hurdle|
|When:||Tuesday, June 12, 2012
Breakfast and Networking: 7:30AM – 8:00AM
Discussion: 8:00AM – 9:00AM
|Where:||OncoMed Pharmaceuticals, Inc.
800 Chesapeake Dr.
Redwood City, CA 94063-4748
|Attire:||Business attire suggested|
|Attendance:||RSVP by June 8 is required
No on-site registrations accepted
Open to C-Suite Executives of
Life Sciences Companies Only.
|Cost:||BayBio Members – FREE
Non-Members – $75.00